India's Suven Life hits record high on US FDA nod for dementia drug trial

Suven Life Sciences

27/08/2024 11:12

** Shares of biopharmaceutical company Suven Life Sciences
 SUVP.NS  rise as much as 5.4% to hit record high at 161 rupees
    ** SUVN says U.S. FDA has accepted its investigational new
drug (IND) application 
    ** Adds, FDA has granted “study may proceed letter” to begin
human study of drug for treating dementia
    ** Trading vol 1.7x 30-day daily avg
    ** Stock up 6.7% so far in August, on track for its third
straight monthly gain
    ** Stock up 90.3% YTD




 (Reporting by Ashish Chandra in Bengaluru)
 ((ashish.chandra@thomsonreuters.com (+91 7982114624))